Authors: Dalen, P Dahl, ML Andersson, K Bertilsson, L

Citation: P. Dalen et al., Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes, BR J CL PH, 49(2), 2000, pp. 180-184

Authors: Dalen, P Dahl, ML Eichelbaum, M Bertilsson, L Wilkinson, GR

Citation: P. Dalen et al., Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes, PHARMACOGEN, 9(6), 1999, pp. 697-706

Authors: Dalen, P Gran, B

Citation: P. Dalen et B. Gran, Studying side effects of dental amalgam, SC J PRIM H, 17(2), 1999, pp. 127-128

Authors: Sandwall, P Lo, MW Jonzon, B Dalen, P Furtek, C Ritter, M Alvan, G McCrea, J Sjoqvist, F

Citation: P. Sandwall et al., Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P4502C19), EUR J CL PH, 55(4), 1999, pp. 279-283